Ivan Poullaos
USA Guide 2024
Up and Coming : Intellectual Property
Email address
[email protected]Contact number
+1 312-558-7962Share profile
Up and Coming
About
Provided by Ivan Poullaos
Practice Areas
Ivan Poullaos is an accomplished patent trial lawyer. He has developed a particular concentration in pharmaceutical Hatch-Waxman and biologics infringement cases. With a degree in chemistry, Ivan is able to take many technical cases to trial with remarkable success. His trial wins in the pharmaceutical sector have been notable. He previously obtained a significant jury trial victory in a case in which our client’s generic Suboxone® and Subutex® tablets were cleared from allegations of patent infringement. As a result of the jury’s favorable finding, the jury awarded no damages against our client, despite a request for more than US$40 million.
Ivan achieved another notable trial win, convincing the court to invalidate the patent covering the active ingredient molecule in the Hepatitis B treatment, Baraclude® (entecavir). The decision was especially important because for the first time, it invalidated as “obvious” a patent on a new chemical compound. The case received extensive press coverage, including articles in Forbes, Bloomberg, Law360, Inside Counsel, and countless IP, FDA, and patent law-related blogs. Ivan also represented this client in the appellate stage of the case, where the district court’s ruling was affirmed.
Well before trial, Ivan's clients look to his strategic advice and analysis to determine the best and most efficient way to achieve their goals, including the potential use of proceedings before the Patent Office.
Chambers Review
USA
Ivan Poullaos is an up-and-coming litigator noted for his work in patent disputes involving highly technical subject matter. He offers demonstrable expertise taking cases to trial.
Strengths
Provided by Chambers
"Ivan has a really good understanding of us as a company, our business and the relevant facts, especially in relation to complex patent issues."
"Ivan has a really good understanding of us as a company, our business and the relevant facts, especially in relation to complex patent issues."